Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: A study protocol using Real-World Data from Catalonia (FantasTIC Study)

Abstract Background: Anticoagulant therapy is used for stroke prevention and proved to be effective and safe in the long term. The study aims to analyse the cost-effectiveness relationship of using of direct-acting oral anticoagulants vs vitamin K antagonists to prevent ischaemic stroke in patients...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2020-09, Vol.99 (36), p.e22054-e22054
Main Authors: Hernández Rojas, Zojaina, Dalmau Llorca, Maria Rosa, Aguilar Martín, Carina, Gonçalves, Alessandra Queiroga, Casajuana, Marc, Fernández-Sáez, José, Rodríguez Cumplido, Dolores, Forcadell Drago, Emma, Carrasco-Querol, Noèlia, Pepió Vilaubí, Josep Maria, Alegret, Josep M.
Format: Article
Language:English
Subjects:
Economic Evaluation Study
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background: Anticoagulant therapy is used for stroke prevention and proved to be effective and safe in the long term. The study aims to analyse the cost-effectiveness relationship of using of direct-acting oral anticoagulants vs vitamin K antagonists to prevent ischaemic stroke in patients with nonvalvular atrial fibrillation, including all the active ingredients marketed in Spain, prescribed for 2 years in the Primary Care service of the Institut Català de la Salut . Methods: Population-based cohort study, in which the cost of the 2 treatment groups will be evaluated. Direct costs (pharmacy, primary care, emergency and hospitalization) and indirect costs (lost productivity) will be included from a social perspective. Effectiveness (assessed as the occurrence of a health event, the 1 of primary interest being stroke) will be determined, with a 2-year time horizon and a 3% discount rate. The average cost of the 2 groups of drugs will be compared using a regression model to determine the factors with the greatest influence on determining costs. We will carry out a univariate (‘one-way’) deterministic sensitivity analysis. Discussion: We hope to provide relevant information about direct and indirect costs of oral anticoagulants, which, together with aspects of effectiveness and safety, could help shape the consensual decision-making of evaluating bodies.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000022054